Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard T Silver

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Haematologica|April 6, 2019
Distinguishing essential thrombocythemia <i>JAK2</i>V617F from polycythemia vera: limitations of erythrocyte valuesRichard T Silver, Spencer Krichevsky
Expert Review of Hematology|May 22, 2015
Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?Hans Carl Hasselbalch, Richard T Silver
Leukemia|April 8, 2026
A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alphaRichard T Silver, Hans Carl Hasselbalch
Expert Review of Hematology|April 4, 2023
Polycythemia vera: aspects of its current diagnosis and initial treatmentRichard T Silver, Ghaith Abu-Zeinah
Hematology (Amsterdam, Netherlands)|February 23, 2016
Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trialsRichard T Silver, Hans Carl Hasselbalch
Expert Review of Hematology|November 12, 2019
Myelofibrosis: best practices, controversies and 2019 updateNicole M Cruz, Usama Gergis, Richard T Silver
Blood|April 27, 2011
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary reportRichard T Silver, Katherine Vandris, Joshua J Goldman
Expert Review of Hematology|February 5, 2013
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosisRichard T Silver, Jean-Jacques Kiladjian, Hans Carl Hasselbalch
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 15, 2015
Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical responseMarco Pizzi, Richard T Silver, Ariella Barel, et al.
Best Practice & Research. Clinical Haematology|November 15, 2016
Management of CML-blast crisisRüdiger Hehlmann, Susanne Saußele, Astghik Voskanyan, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Haematologica|April 6, 2019
Distinguishing essential thrombocythemia <i>JAK2</i>V617F from polycythemia vera: limitations of erythrocyte valuesRichard T Silver, Spencer Krichevsky
Expert Review of Hematology|May 22, 2015
Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?Hans Carl Hasselbalch, Richard T Silver
Leukemia|April 8, 2026
A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alphaRichard T Silver, Hans Carl Hasselbalch
Expert Review of Hematology|April 4, 2023
Polycythemia vera: aspects of its current diagnosis and initial treatmentRichard T Silver, Ghaith Abu-Zeinah
Hematology (Amsterdam, Netherlands)|February 23, 2016
Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trialsRichard T Silver, Hans Carl Hasselbalch
Expert Review of Hematology|November 12, 2019
Myelofibrosis: best practices, controversies and 2019 updateNicole M Cruz, Usama Gergis, Richard T Silver
Blood|April 27, 2011
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary reportRichard T Silver, Katherine Vandris, Joshua J Goldman
Expert Review of Hematology|February 5, 2013
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosisRichard T Silver, Jean-Jacques Kiladjian, Hans Carl Hasselbalch
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 15, 2015
Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical responseMarco Pizzi, Richard T Silver, Ariella Barel, et al.
Best Practice & Research. Clinical Haematology|November 15, 2016
Management of CML-blast crisisRüdiger Hehlmann, Susanne Saußele, Astghik Voskanyan, et al.
Pageof 9